Meta-Analysis of Gut Dysbiosis in Parkinson's DiseaseOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined gut microbiota dysbiosis in Parkinson's disease (PD) using 16S ribosomal RNA gene sequencing. The researchers combined their own dataset with four previously reported datasets from other countries to meta-analyze shared patterns of gut dysbiosis in PD. They also developed a new pathway-analysis method, the Kyoto Encyclopedia of Genes and Genomes orthology set enrichment analysis, to interpret functional changes in the microbiota. The goal was to identify gut dysbiosis signatures in PD that hold across different national populations, since microbiota variability across countries had previously obscured shared findings.
Who was studied?
The primary cohort consisted of 223 patients with PD and 137 controls. This dataset was then meta-analyzed together with four previously published datasets from the United States, Finland, Russia, and Germany. An additional 12 datasets not included in the meta-analysis were used afterward to inspect and cross-check specific bacterial findings.
What were the most important findings?
After adjusting for confounders including body mass index, constipation, sex, age, and catechol-O-methyl transferase inhibitor use, the genera Akkermansia and Catabacter, and the family Akkermansiaceae, were increased in PD, while the genera Roseburia and Faecalibacterium and the family Lachnospiraceae ND3007 group were decreased. Catechol-O-methyl transferase inhibitor intake was separately associated with a marked increase in the family Lactobacillaceae. Checking these results against 12 additional independent datasets confirmed that the increase in Akkermansia was a consistent finding.
What are the greatest implications of this study?
By combining datasets across the United States, Finland, Russia, Germany, and the authors' own cohort, the study identifies gut dysbiosis features in PD that are shared across countries rather than population-specific artifacts. The consistent increase in Akkermansia and Akkermansiaceae, alongside depletion of short-chain-fatty-acid-associated taxa like Roseburia and Faecalibacterium, points to reproducible microbial targets for further mechanistic study in PD. The finding that a PD medication itself alters the microbiome (increasing Lactobacillaceae) also underscores the need to account for medication effects when interpreting gut-brain axis research in PD.